

MI: Secondary prevention (CG48 update) review questions

Chapter	Review questions	Outcomes
Lifestyle	What is the clinical and cost effectiveness of omega-3 fatty acids in all patients with myocardial infarction?	<ul style="list-style-type: none"> • Mortality (all cause, cardiac or sudden) • Quality of life • Re-infarction • Revascularisation • Stroke • Readmission/hospitalisation • Side effects/adverse events.
Lifestyle	What is the clinical and cost effectiveness of oily fish consumption in all patients with myocardial infarction?	<ul style="list-style-type: none"> • Mortality (all cause, cardiac or sudden) • Quality of life • Re-infarction • Revascularisation • Stroke • Readmission/hospitalisation • Side effects/adverse events.
Cardiac rehabilitation	Which factors are associated with patients' uptake and adherence to a cardiac rehabilitation programme after an MI?	<ul style="list-style-type: none"> • Factors associated with patient's uptake and adherence to cardiac rehabilitation programme. • Factors associated with healthcare professionals in promoting patient's uptake and adherence to cardiac rehabilitation programme.
Cardiac rehabilitation	Which interventions designed to increase engagement in and/or adherence to cardiac rehabilitation programmes are effective and cost effective in people who have had an MI?	<ul style="list-style-type: none"> • Adherence • Uptake • Completion • Reasons for withdrawal • Quality of life • Adverse effects.
Drug therapy	What is the clinical and cost effectiveness of adding ACE inhibitors versus placebo to improve outcome in people after an MI and is there an optimal duration?	<ul style="list-style-type: none"> • Mortality (all cause, cardiac or sudden) • Quality of life • Re-infarction • Revascularisation • Stroke • Readmission/hospitalisation • Side effects/adverse events.
Drug therapy	Is there an optimal time for ACE inhibitors to be initiated in people who have had a MI?	<ul style="list-style-type: none"> • Mortality (all cause, cardiac or sudden) • Quality of life • Re-infarction • Revascularisation • Stroke • Readmission/hospitalisation • Side effects/adverse events.
Drug therapy	Is early dose titration of ACE inhibitors in hospital more clinically and cost effective than dose titration over an extended period of time in people who have had a MI?	<ul style="list-style-type: none"> • Mortality (all cause, cardiac or sudden) • Quality of life • Re-infarction • Revascularisation • Stroke

MI: Secondary prevention (CG48 update) review questions

Chapter	Review questions	Outcomes
		<ul style="list-style-type: none"> • Readmission/hospitalisation • Side effects/adverse events.
Drug therapy	What is the clinical and cost effectiveness of adding ACE inhibitors versus ARBs or in combination versus ACE inhibitors to improve outcomes in people after an MI?	<ul style="list-style-type: none"> • Mortality (all cause, cardiac or sudden) • Quality of life • Re-infarction • Revascularisation • Stroke • Readmission/hospitalisation • Side effects/adverse events.
Drug therapy	What optimal duration clopidogrel should be continued in patients after MI?	<ul style="list-style-type: none"> • Mortality (all cause, cardiac or sudden) • Quality of life • Re-infarction • Revascularisation • Stroke • Readmission/hospitalisation • Side effects/adverse events.
Drug therapy	In people with a proven MI in the past who were not initiated on dual antiplatelet therapy (clopidogrel, prasugrel or ticagrelor in combination with aspirin), should this be initiated?	<ul style="list-style-type: none"> • Mortality (all cause, cardiac or sudden) • Quality of life • Re-infarction • Revascularisation • Stroke • Readmission/hospitalisation • Side effects/adverse events.
Drug therapy	What is the most clinically and cost effective combination of antiplatelet and anticoagulant therapies for people who have had an MI and an indication for anticoagulation?	<ul style="list-style-type: none"> • Mortality (all cause, cardiac or sudden) • Quality of life • Re-infarction • Revascularisation • Stroke • Readmission/hospitalisation • Side effects/adverse events.
Drug therapy	Is there an optimal time for a beta-blocker to be initiated in people who have had a MI?	<ul style="list-style-type: none"> • Mortality (all cause, cardiac or sudden) • Quality of life • Re-infarction • Revascularisation • Stroke • Readmission/hospitalisation • Side effects/adverse events.
Drug therapy	What is the clinical and cost effectiveness of adding a beta-blocker versus placebo to improve outcome in people after a MI i) with and ii) without left ventricular dysfunction and is there an optimal duration?	<ul style="list-style-type: none"> • Mortality (all cause, cardiac or sudden) • Quality of life • Re-infarction • Revascularisation • Stroke • Readmission/hospitalisation • Side effects/adverse events.

MI: Secondary prevention (CG48 update) review questions